Successful Treatment of Mitral Regurgitation after Transapical Transcatheter Aortic Valve Implantation by Percutaneous Edge-to-edge Mitral Valve Repair (MitraClip®) —The First Combination Therapy Performed in Japan—

Atsushi Okada1, Hideaki Kanzaki1, Makoto Amaki1, Yu Kataoka1, Koji Miyamoto1, Yasuhiro Hamatani1, Masashi Fujino1, Hiroyuki Takahama1, Takuya Hasagawa1, Yusuke Shimahara2, Yoshiaki Morita3, Yasuo Sugano1, Kengo Kusano1, Yoshihiko Ohnishi4, Tomoyuki Fujita1, Junjiro Kobayashi2, Toshihisa Anzai1 and Satoshi Yasuda1

Abstract:
A 75-year-old man with a history of inferior myocardial infarction was admitted with symptoms of progressive heart failure 3 months after undergoing transapical transcatheter aortic valve implantation (TAVI). Echocardiography revealed severe mitral regurgitation (MR) caused by posterior leaflet tethering, without traumatic injury of the mitral valve or chordae. The patient was successfully treated by percutaneous edge-to-edge mitral valve repair (MitraClip®). This case highlights the role of MitraClip® in high-risk patients suffering from MR, and suggests that apical contractile loss or adhesion caused by apical puncture and suturing in transapical TAVI may be one of the mechanisms of worsening MR.

Key words: percutaneous edge-to-edge mitral valve repair, MitraClip, mitral regurgitation, tethering, transcatheter aortic valve implantation, TAVI

(Intern Med Advance Publication) (DOI: 10.2169/internalmedicine.9663-17)
tethering with mitral annular diameter of 40 mm. Enhanced computed tomography confirmed the patency of the bypass grafts and revealed an abdominal aortic aneurysm of 38 mm in diameter with aortic plaques. Given the high risk of operative mortality (STS-PROM score, 10.6%; EuroSCORE II, 10.8%) and aortic anatomy, our heart team decided that transapical TA VI (TA-TA VI) was indicated.

TA-TA VI was performed via left minithoracotomy in the 5th intercostal space, with a 29-mm SAPIEN XT valve using the Ascendra+ system (Edwards Lifesciences Corp., Irvine, CA, USA). Intraoperative monitoring by transesophageal echocardiography detected mild paravalvular aortic regurgitation, but there was no acute MR or traumatic exacerbation. His postoperative course was uneventful. However, echocardiography at 1 week after TA VI revealed that the MR had worsened to grade 3+ with no obvious change in the LV function (ejection fraction, 52%; Dd/Ds, 57/45 mm).

Three months later, he was readmitted with symptoms of progressive heart failure with new-onset atrial fibrillation. Echocardiography revealed grade 4+ MR (Fig. 1A) and LV dysfunction (ejection fraction, 35%; Dd/Ds, 60/50 mm). A further analysis by transesophageal echocardiography showed the worsening of the posterior leaflet tethering (tenting height, 9.9 mm; tenting area, 1.49 cm²) without mitral valve prolapse or chordal rupture (Fig. 1B). Non-contrast cardiac magnetic resonance imaging was performed to assess the LV dysfunction, which revealed adhesion of the LV apical area by tagged cine magnetic resonance imaging (Fig. 2A). The assessment of the myocardial substrate by native T1 mapping suggested diffuse myocardial fibrosis and localized thinning of the LV apex in color maps of the native T1 values (Fig. 2B).

Our heart team discussed the surgical indications for symptomatic MR and the indications for percutaneous edge-to-edge mitral valve repair using a MitraClip®, and the eligibility committee confirmed that the patient was eligible for inclusion in the AVJ-514 Japan trial (ClinicalTrials.gov NCT...
02520310) (3). As previously described (3, 4), the MitraClip® system was introduced via the right femoral vein and delivered through a transseptal approach (Fig. 1C-E). MR was successfully reduced to grade 1+ after the application of the first clip, which grasped the middle of A2/P2 (Fig. 1F-G). The procedure was successfully completed, and the rest of his hospitalization was uneventful. After 12 months of follow up, he remained minimally asymptomatic (New York Heart Association functional class I) without any recurrence of significant MR or atrial fibrillation (ejection fraction, 47%; Dd/Ds, 60/45 mm; Fig. 3A-C).

Discussion

We reported the case of a patient with pre-existing mitral tethering whose MR worsened after TA-TAVI. The patient was successfully treated by percutaneous edge-to-edge mitral valve repair using a MitraClip®.

Previous reports have described improvements of coexisting MR in the majority of patients after TAVI, as a reduction of the LV pressure, LV reverse remodeling, and the improvement of mitral leaflet tethering have been suggested to contribute to a reduction of MR (5-10). Nevertheless, the worsening MR is reported in approximately 3-10% of cases (5, 6, 11, 12).

Dilation of the mitral annulus (>35.5 mm)-which was observed in our patient-and mitral calcification have been reported to predict persistent MR after TAVI (12). However, the mechanisms of persistent or worsening MR after TAVI have not been fully elucidated. Traumatic injury of the mi-
Central leaflet or mitral chordae, impingement of the anterior mitral leaflet by an aortic prosthesis, or mechanical dyssynchrony due to new left bundle branch block have previously been suggested as possible mechanisms (13, 14). In our case, no traumatic injury of the mitral apparatus or mitral impingement was noted on echocardiography, and no left bundle branch block was noted on electrocardiography. However, transesophageal echocardiography revealed worsening MR from decreased mitral valve coaptation due to worsened posterior tethering. Furthermore, LV apical contractile loss and apical adhesion (revealed by cardiac magnetic resonance imaging), which results in decreased longitudinal contraction or loss of apical torsion (15-18), might have led to a worsening of the posterior leaflet tethering and decreased mitral valve coaptation.

While this case highlights the role of percutaneous edge-to-edge mitral valve repair in high-risk patients suffering from MR after TAVI, apical puncture and suturing in TA-TAVI may be mechanisms of worsening tethering and worsening MR in patients with pre-existing MR due to leaflet tethering.

Author’s disclosure of potential Conflicts of Interest (COI). Research Funding: Satoshi Yasuda, Abbott Vascular Inc. 

References
1. Sawa Y, Takayama M, Mitsudo K, et al. Clinical efficacy of transcatheter aortic valve replacement for severe aortic stenosis in high-risk patients: the PREVAIL JAPAN trial. Surg Today 45: 34-43, 2015.
2. Kobayashi J, Shimahara Y, Fujita T, et al. Early results of simultaneous transaortic transcatheter aortic valve implantation and total arterial off-pump coronary artery revascularization in high-risk patients. Circ J 80: 1946-1950, 2016.
3. Hayashida K, Yasuda S, Matsumoto T, et al. AVJ-514 Trial: Baseline characteristics and 30-day outcomes following MitraClip® treatment in a Japanese cohort. Circ J 81: 1116-1122, 2017.
4. Grasso C, Capodanno D, Tamburino C, Ohno Y. Current status and clinical development of transcatheter approaches for severe mitral regurgitation. Circ J 79: 1164-1171, 2015.
5. Toggweiler S, Boone RH, Rodés-Cabau J, et al. Transcatheter aortic valve replacement: outcomes of patients with moderate or severe mitral regurgitation. J Am Coll Cardiol 59: 2068-2074, 2012.
6. Hekimian G, Detaint D, Messika-Zeitoun D, et al. Mitral regurgitation in patients referred for transcatheter aortic valve implantation using the Edwards Sapien prosthesis: mechanisms and early postprocedural changes. J Am Soc Echocardiogr 25: 160-165, 2012.

7. Fojt R, Moťovská Z, Budera P, Malý M, Straka Z. Prognostic impact and change of concomitant mitral regurgitation after surgical or transcatheter aortic valve replacement for aortic stenosis. J Cardiol 67: 526-530, 2016.

8. Giordana F, Capriolo M, Frea S, et al. Impact of TAVI on mitral regurgitation: a prospective echocardiographic study. Echocardiography 30: 250-257, 2013.

9. Wilbring M, Tugtekin SM, Ritzmann M, et al. Transcatheter aortic valve implantation reduces grade of concomitant mitral and tricuspid valve regurgitation and pulmonary hypertension. Eur J Cardiothorac Surg 46: 818-824, 2014.

10. Shibayama K, Harada K, Berdejo J, et al. Effect of transcatheter aortic valve replacement on the mitral valve apparatus and mitral regurgitation: real-time three-dimensional transesophageal echocardiography study. Circ Cardiovasc Imaging 7: 344-351, 2014.

11. O’Sullivan CJ, Stortecky S, Bütikofer A, et al. Impact of nitrate regurgitation on clinical outcomes of patients with low-ejection fraction, low-gradient severe aortic stenosis undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv 8: e001895, 2015.

12. Cortés C, Amat-Santos IJ, Nombela-Franco L, et al. Mitral regurgitation after transcatheter aortic valve replacement: prognosis, imaging predictors, and potential management. JACC Cardiovasc Interv 9: 1603-1614, 2016.

13. Al-Attar N, Ghodbane W, Himbert D, et al. Unexpected complications of transapical aortic valve implantation. Ann Thorac Surg 88: 90-94, 2009.

14. López-Aguilera J, Mesa-Rubio D, Ruiz-Oriz M, et al. Mitral regurgitation during transcatheter aortic valve implantation: the same complication with a different mechanism. J Invasive Cardiol 26: 603-608, 2014.

15. Løgstrup BB, Andersen HR, Thuesen L, et al. Left ventricular global systolic longitudinal deformation and prognosis 1 year after femoral and apical transcatheter aortic valve implantation. J Am Soc Echocardiogr 26: 246-254, 2013.

16. Meyer CG, Frick M, Lotfi S, et al. Regional left ventricular function after transapical vs. transfemoral transcatheter aortic valve implantation analysed by cardiac magnetic resonance feature tracking. Eur Heart J Cardiovasc Imaging 15: 1168-1176, 2014.

17. Biere L, Pinaud F, Delépine S, et al. CMR assessment after a transapical-transcatheter aortic valve implantation. Eur J Radiol 83: 303-308, 2014.

18. Ribeiro HB, Dahou A, Urena M, et al. Myocardial injury after transaortic versus transapical transcatheter aortic valve replacement. Ann Thorac Surg 99: 2001-2009, 2015.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).